Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

被引：2
|
作者：
Jindy, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Nguyen, Charles B.
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Emamekhoo, Hamid
Hoimes, Christopher J.
Khaki, Ali Raza
Gupta, Shilpa
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Cleveland Clin, Cleveland, OH USA
[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[12] Univ Wisconsin, Madison, WI USA
[13] Duke Univ, Duke Canc Inst, Durham, NC USA
[14] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA
[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[16] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[17] Fred Hutchinson Canc Ctr, Seattle, WA USA
[18] Dana Farber Canc Inst, Boston, MA USA
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA
[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-12099; 261-492-3532-2370-7650-2700; 261-566-9263; 4; 2; 3224; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [1] Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.
    Jindal, Tanya
    Alhalabi, Omar
    Nguyen, Charles B.
    Bakaloudi, Dimitra Rafailia
    Nizam, Amanda
    Bilen, Mehmet Asim
    Basu, Arnab
    Zakharia, Yousef
    Milowsky, Matthew I.
    Brown, Jason R.
    Kilari, Deepak
    Shah, Sumit
    Emamekhoo, Hamid
    Grivas, Petros
    Hoimes, Christopher J.
    Gupta, Shilpa
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 651 - 651
  • [2] Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Zhang, Li
    Jiang, Cindy
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Shah, Sumit
    Hoimes, Christopher J.
    Davis, Nancy B.
    Gupta, Shilpa
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Khaki, Ali Raza
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Shah, Sumit
    Zakharia, Yousef
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Grivas, Petros
    Gupta, Shilpa
    Hoimes, Christopher J.
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.
    Nizam, Amanda
    Jindal, Tanya
    Jiang, Cindy Y.
    Alhalabi, Omar
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Davidsohn, Matthew P.
    Nguyen, Charles B.
    Oh, Eugene
    Taylor, Amy K.
    Lemke, Emily
    Kilari, Deepak
    Hoimes, Christopher J.
    Emamekhoo, Hamid
    Gupta, Shilpa
    Bellmunt, Joaquim
    Grivas, Petros
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 537 - 537
  • [5] Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.
    Koshkin, Vadim S.
    Sun Yilun
    Freeman, Dory
    Osterman, Chelsea K.
    Su, Christopher
    Natesan, Divya
    Khaki, Ali Raza
    Makrakis, Dimitrios
    Jain, Jayanshu
    Olsen, Anders
    Basu, Arnab
    Barata, Pedro C.
    Zakharia, Yousef
    Bilen, Mehmet Asim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Milowsky, Matthew, I
    Kilari, Deepak
    Sonpavde, Guru
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Petrylak, Daniel P.
    Powles, Thomas
    Rosenberg, Jonathan E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94
  • [7] Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Jiang, Cindy
    Alhalabi, Omar
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Davidsohn, Matthew
    Nizam, Amanda
    Taylor, Amy K.
    Nguyen, Charles B.
    Kilari, Deepak
    Pywell, Cameron
    Davis, Nancy B.
    Emamekhoo, Hamid
    Sonpavde, Guru P.
    Gupta, Shilpa
    Bellmunt, Joaquim
    Grivas, Petros
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan
    Hara, Takuto
    Matsushita, Yuto
    Harada, Kenichi
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (06) : 696 - 698
  • [9] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135
  • [10] Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
    Koshkin, Vadim S.
    Henderson, Nicholas
    James, Marihella
    Natesan, Divya
    Freeman, Dory
    Nizam, Amanda
    Su, Christopher T.
    Khaki, Ali Raza
    Osterman, Chelsea K.
    Glover, Michael J.
    Chiang, Ryan
    Makrakis, Dimitrios
    Talukder, Rafee
    Lemke, Emily
    Olsen, T. Anders
    Jain, Jayanshu
    Jang, Albert
    Ali, Alicia
    Jindal, Tanya
    Chou, Jonathan
    Friedlander, Terence W.
    Hoimes, Christopher
    Basu, Arnab
    Zakharia, Yousef
    Barata, Pedro C.
    Bilen, Mehmet A.
    Emamekhoo, Hamid
    Davis, Nancy B.
    Shah, Sumit A.
    Milowsky, Matthew I.
    Gupta, Shilpa
    Campbell, Matthew T.
    Grivas, Petros
    Sonpavde, Guru P.
    Kilari, Deepak
    Alva, Ajjai S.
    CANCER, 2022, 128 (06) : 1194 - 1205
12345